Italia - italiano - Ministero della Salute

norbrook laboratories (ireland) limited - acido clavulanico, amoxicillina triidrato - acido clavulanico - 100 milligrammo (i); amoxicillina triidrato - nd, amoxicillina triidrato - nd ; acido clavulanico - 100 milligrammo (i), acido clavulanico - 100 mg; amoxicillina triidrato - nd, amoxicillina triidrato - nd ; acido clavulanico - 100 mg - amoxicillin and enzyme inhibitor

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

as grindeks - metformina e sitagliptina - metformina e sitagliptina

Italia - italiano - Ministero della Salute

norbrook laboratories (ireland) limited - acido clavulanico, amoxicillina triidrato - acido clavulanico - 10 milligrammo (i); amoxicillina triidrato - 40 milligrammo (i), acido clavulanico - 50 milligrammo (i); amoxicillina triidrato - 200 milligrammo (i), amoxicillina triidrato - 200 mg; acido clavulanico - 50 mg, amoxicillina triidrato - 40 mg; acido clavulanico - 10 mg, acido clavulanico - 50 mg; amoxicillina triidrato - 200 mg, acido clavulanico - 10 mg; amoxicillina triidrato - 40 mg - amoxicillin and enzyme inhibitor

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

geymonat s.p.a. - ticarcillina e inibitori enzimatici - ticarcillina e inibitori enzimatici

Unione Europea - italiano - EMA (European Medicines Agency)

bayer ag - riociguat - ipertensione, polmonare - antipertensivi per l'ipertensione arteriosa polmonare - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l'efficacia è stata dimostrata in un pah della popolazione eziologie di idiopatica o ereditaria ipa o pah associata a malattia del tessuto connettivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabete mellito, tipo 2 - farmaci usati nel diabete - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - agenti antineoplastici - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanoma - agenti antineoplastici - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 e 5. il trattamento adiuvante di melanomadabrafenib in combinazione con trametinib è indicato per il trattamento adiuvante di pazienti adulti con melanoma in stadio iii con un braf v600 mutazione, a seguito di una completa resezione. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.